Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16085
Title: Amyloid-Related memory decline in preclinical Alzheimer's Disease is dependent on APOE ε4 and is detectable over 18-months
Austin Authors: Thai, Christine;Villemagne, Victor L ;Laws, Simon M;Ames, David;Ellis, Kathryn A;Rainey-Smith, Stephanie R;Martins, Ralph N;Masters, Colin L ;Rowe, Christopher C ;Maruff, Paul;Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Department of Psychology, RMIT University, Melbourne, Australia
The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
Department of Neurology, Warren Alpert School of Medicine, Brown University, Providence, Rhode Island,USA
Department of Neurology, Rhode Island Hospital, Providence, Rhode Island, USA
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Centre of Excellence for Alzheimer’s Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australia
Sir James McCusker Alzheimer’s Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia
Co-operative Research Centre for Mental Health, Perth, Western Australia, Australia
National Ageing Research Institute, Parkville, Victoria, Australia
Academic Unit for Psychiatry of Old Age, St. Vincent’s Health, The University of Melbourne, Kew, Victoria, Australia
Cogstate Ltd., Melbourne, Victoria, Australia
Issue Date: 2-Oct-2015
metadata.dc.date: 2015-10-02
Publication information: PLoS One 2016; 10(10): e0139082
Abstract: High levels of β-amyloid (Aβ) in the brain and carriage of the APOE ε4 allele have each been linked to cognitive impairment in cognitively normal (CN) older adults. However, the relationship between these two biomarkers and cognitive decline is unclear. The aim of this study was to investigate the relationship between cerebral Aβ level, APOE ε4 carrier status, and cognitive decline over 18 months, in 317 cognitively healthy (CN) older adults (47.6% males, 52.4% females) aged between 60 and 89 years (Mean = 69.9, SD = 6.8). Cognition was assessed using the Cogstate Brief Battery (CBB) and the California Verbal Learning Test, Second Edition (CVLT-II). Planned comparisons indicated that CN older adults with high Aβ who were also APOE ε4 carriers demonstrated the most pronounced decline in learning and working memory. In CN older adults who were APOE ε4 non-carriers, high Aβ was unrelated to cognitive decline in learning and working memory. Carriage of APOE ε4 in CN older adults with low Aβ was associated with a significantly increased rate of decline in learning and unexpectedly, improved cognitive performance on measures of verbal episodic memory over 18 months. These results suggest that Aβ and APOE ε4 interact to increase the rate of cognitive decline in CN older adults and provide further support for the use of Aβ and APOE ε4 as biomarkers of early Alzheimer's disease.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16085
DOI: 10.1371/journal.pone.0139082
ORCID: 0000-0003-3910-2453
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/26430784
Type: Journal Article
Subjects: Alzheimer Disease
Amyloid beta-peptides
Memory disorders
Apolipoprotein E4
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Dec 4, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.